Principal Financial Group Inc. Decreases Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)
Principal Financial Group Inc. lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 31.6% during the third ...
Is Exelixis, Inc. (EXEL) the Best Performing Biotech Stock in 2024?
We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at ...
Yahoo Finance2d
Exelixis, Inc. (EXEL)
In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against the other biotech stocks. The Booming Biotechnology Sector The biotechnology sector is expanding ...
Investor's Business Daily on MSN7h
Stocks Showing Rising Market Leadership: Arcellx Earns 82 RS Rating
Arcellx shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.
stocknews10d
Is Exelixis Positioned to Capitalize on Emerging Cancer Therapies?
In the expanding oncology market, Exelixis (EXEL) is gaining attention with its strong pipeline and impressive stock ...
Pharmaceutical Technology2d
Zanzalintinib fumarate by Exelixis for Oropharyngeal Cancer: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Oropharyngeal Cancer.
Exelixis initiated with a Buy at Brookline
Brookline initiated coverage of Exelixis (EXEL) with a Buy rating.Don't Miss Our Christmas Offers:Discover the latest stocks recommended by top ...